Last reviewed · How we verify
Vehicle of KPI-121 0.25%
Vehicle of KPI-121 0.25% is a corticosteroid Small molecule drug developed by Kala Pharmaceuticals, Inc.. It is currently in Phase 3 development for Treatment of non-infectious uveitis affecting the posterior segment of the eye. Also known as: Vehicle of KPI-121 0.25% Ophthalmic Suspension.
KPI-121 is a corticosteroid
KPI-121 is a corticosteroid Used for Treatment of non-infectious uveitis affecting the posterior segment of the eye.
At a glance
| Generic name | Vehicle of KPI-121 0.25% |
|---|---|
| Also known as | Vehicle of KPI-121 0.25% Ophthalmic Suspension |
| Sponsor | Kala Pharmaceuticals, Inc. |
| Drug class | corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
KPI-121 is a corticosteroid that is designed to provide sustained release of dexamethasone, a potent anti-inflammatory agent. This allows for reduced dosing frequency and improved patient compliance. The sustained release formulation is intended to provide a consistent therapeutic effect over an extended period.
Approved indications
- Treatment of non-infectious uveitis affecting the posterior segment of the eye
Common side effects
- Increased intraocular pressure
Key clinical trials
- Safety and Efficacy of KPI-121 in Subjects With DED (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease (PHASE2)
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (PHASE2)
- Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vehicle of KPI-121 0.25% CI brief — competitive landscape report
- Vehicle of KPI-121 0.25% updates RSS · CI watch RSS
- Kala Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Vehicle of KPI-121 0.25%
What is Vehicle of KPI-121 0.25%?
How does Vehicle of KPI-121 0.25% work?
What is Vehicle of KPI-121 0.25% used for?
Who makes Vehicle of KPI-121 0.25%?
Is Vehicle of KPI-121 0.25% also known as anything else?
What drug class is Vehicle of KPI-121 0.25% in?
What development phase is Vehicle of KPI-121 0.25% in?
What are the side effects of Vehicle of KPI-121 0.25%?
Related
- Drug class: All corticosteroid drugs
- Manufacturer: Kala Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Treatment of non-infectious uveitis affecting the posterior segment of the eye
- Also known as: Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Compare: Vehicle of KPI-121 0.25% vs similar drugs
- Pricing: Vehicle of KPI-121 0.25% cost, discount & access